Home › Funds › ACUTA CAPITAL PARTNERS, LLC › STRO
ACUTA CAPITAL PARTNERS, LLC position in STRO
SUTRO BIOPHARMA INC · Health Care
ACUTA CAPITAL PARTNERS, LLC reported holding 270,251 shares of STRO (SUTRO BIOPHARMA INC) in its Q2 2026 13F filing — a position valued at US$9.0M, representing 6.25% of its reported portfolio and ranking #4 among its reported holdings. ACUTA CAPITAL PARTNERS, LLC has disclosed STRO holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ACUTA CAPITAL PARTNERS, LLC's STRO position evolved
ACUTA CAPITAL PARTNERS, LLC first disclosed a stake in STRO in Q4 2025 at 67,451 shares (US$780K). The position peaked in Q2 2026 at 270,251 shares, worth US$9.0M. Across 3 filings, ACUTA CAPITAL PARTNERS, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 270,251 shares valued at US$9.0M. Notable position changes include a 299% increase in Q1 2026 (shares rose 33% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 67.45K | $780.41K | New |
| Q1 2026 | 269.43K | $6.71M | Add |
| Q2 2026 | 270.25K | $8.97M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About STRO and 13F data
STRO (SUTRO BIOPHARMA INC) is a Health Care company. 45 other funds we track also report a position in STRO — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$43.3M), BVF INC/IL (US$41.6M), Affinity Asset Advisors, LLC (US$38.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding STRO
- PERCEPTIVE ADVISORS LLC 1.30M sh · $43.32M · Q2 2026
- BVF INC/IL 1.25M sh · $41.56M · Q2 2026
- Affinity Asset Advisors, LLC 1.17M sh · $38.93M · Q2 2026
- Samsara BioCapital, LLC 1.06M sh · $35.29M · Q2 2026
- Kynam Capital Management, LP 872.56K sh · $28.97M · Q2 2026
- Velan Capital Investment Management LP 512.16K sh · $17.00M · Q2 2026
- ADAR1 Capital Management, LLC 404.01K sh · $13.41M · Q2 2026
- Merck & Co., Inc. 272.35K sh · $9.04M · Q2 2026
- KVP Capital Advisors, LP 226.57K sh · $7.52M · Q2 2026
- Seven Fleet Capital Management LP 159.12K sh · $3.79M · Q2 2026
More on ACUTA CAPITAL PARTNERS, LLC
FAQ
How long has ACUTA CAPITAL PARTNERS, LLC held STRO?
ACUTA CAPITAL PARTNERS, LLC has disclosed STRO holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is ACUTA CAPITAL PARTNERS, LLC's current position in STRO?
As of Q2 2026, ACUTA CAPITAL PARTNERS, LLC holds 270.25K shares of STRO (SUTRO BIOPHARMA INC), valued at $8.97M, representing 6.25% of its reported portfolio and ranking #4.
Has ACUTA CAPITAL PARTNERS, LLC been buying or selling STRO?
In the latest 13F filing (Q2 2026), ACUTA CAPITAL PARTNERS, LLC held unchanged its position in STRO. The position peaked in Q2 2026 at 270.25K shares.
Which other funds hold STRO?
Other major institutional holders of STRO include PERCEPTIVE ADVISORS LLC, BVF INC/IL, Affinity Asset Advisors, LLC, among 45 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.